BioGaia ABBGLAF 100 Gross Margin % is 71.61% as of Mar. 2026, which is 2% below its 10-year median of 73.33. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 938 Drug Manufacturers companies, BioGaia AB ranks better than 85.71% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. BioGaia AB's Gross Profit for the
three
months ended in Mar. 2026 was $28.6 Mil. BioGaia AB's Revenue for the
three
months ended in Mar. 2026 was $40.0 Mil. Therefore, BioGaia AB's Gross Margin % for the quarter that ended in Mar. 2026 was 71.61%.
The historical rank and industry rank for BioGaia AB's Gross Margin % or its related term are showing as below:
BGLAF'
s Gross Margin % Range Over the Past 10 Years
Min: 72.45 Med: 73.33 Max: 75.34
Current: 72.97
During the past 13 years, the highestGross Margin % of BioGaia AB was 75.34%. The lowest was 72.45%. And the median was 73.33%.
BGLAF's Gross Margin % is ranked better than 85.71% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs BGLAF: 72.97
BioGaia AB had a gross margin of 71.61% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for BioGaia AB was -0.20% per year.
BioGaia AB (OTCPK:BGLAF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioGaia AB had a gross margin of 71.61% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BioGaia AB Gross Margin % Related Terms
BioGaia AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BioGaia AB (BGLAF) has a Gross Margin % of 71.61% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on BioGaia AB and its competitors. This is near median its historical median of 73.33. Over the past decade, BioGaia AB's Gross Margin % has ranged from 72.45 to 75.34. According to the industry distribution chart, BioGaia AB ranks #134 out of 938 companies in the Drug Manufacturers industry, placing it in the top 14.3%.
Is BioGaia AB's Gross Margin % too high?
BioGaia AB's current Gross Margin % of 71.61% is near median its 10-year median of 73.33. Over the past 10 years, this metric has ranged from a low of 72.45 to a high of 75.34. The Drug Manufacturers industry median Gross Margin % is 48.44. BioGaia AB's value of 71.61% is 47.8% above this industry median. Based on the distribution chart, BioGaia AB ranks #134 out of 938 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #134 out of 938 companies for Gross Margin %. This places BioGaia AB in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.44. BioGaia AB's value of 71.61% is 47.8% above this benchmark. Historically, BioGaia AB's own Gross Margin % has ranged from 72.45 to 75.34 over the past decade. While the company's 10-year median is 73.33 vs. the industry median of 48.44, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Gross Margin % of 71.61% is 47.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Gross Margin % is 71.61%, which is near median its own 10-year median of 73.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Gross Margin % of 71.61%. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Gross Margin % is 71.61%, which is near median its 10-year median of 73.33 and 47.8% above the Drug Manufacturers industry median of 48.44. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Gross Margin % is 71.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Gross Margin %: 71.61% (near median its 10-year median of 73.33)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 47.8% above the Drug Manufacturers median (#134 of 938)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
